PDCD1 and lymphoma: Similar with solid cancer, the responsiveness to anti-PD-1 therapies in lymphoma is also mainly determined by underlying biologic features of the lymphoma cell itself, such as overexpression of PD-1 ligands (i.e., PD-L1 encoded by CD274), as well as the composition of the TME (Kline et al., 2020).